Our mission is to lessen the burden of breast cancer by using a multidisciplinary approach to discover novel mechanisms of breast cancer pathogenesis and test innovative, basic science-based therapeutic strategies.

Our amazing patient advocates at #ASCO2025

Dr. Laura Huppert presents trial-in-progress TBCRC-067 ENCORE @ASCO. Improving understanding of real world sequential ADC use in breast cancer. #ASCO2025

RT @ncasasanta: Lots of buzz around @theTBCRC 040 PREDICT-DNA trial presented by Dr. Natasha Hunter 🐝 ➰.➡️ Among HER2+ & TNBC pts receiving….

RT @nlinmd: TBCRC 040 (PREDICT-DNA trial): Dr. Natasha Hunter presents -.-HER2+ or TN pts with MRD assay after NAT and pre surgery .-in TNB….

RT @ncasasanta: @neil_iyengar shares @theTBCRC 054 phase 1 trial of exercise therapy in pts w/ HR+ MBC on ET + CKD4/6i assigned to 1/4 exer….

RT @Elkhanany: Another great study run by @TheTBCRC and lead by my dear colleague Julie Nangia at @BCMCancerCenter. 042 used Ruxolitinib fo….

.@adawaksmd presents RCT TBCRC052/MARGOT at #SABCS24 showing margetuximab (TMP) no statistically sig improved pCR rate vs THP for mostly cT2N0 disease though 10% higher numerically. Did not differ by HR status. Both well tolerated regimens @DFCI_BreastOnc

We are grateful for the support of @BCRFcure & @SusanGKomen. See you soon at #SABCS24!.

RT @HennessyMaeve: @CanResUCC @BreakthroCancer @SNM_MI @CUH_Cork @RoisinMConnolly @UCCCancerTrials @UCCResearch @UCCMedHealth @UCC Delighte….

TBCRC049 presented by PI @barbaraobrienmd demonstrated symptom and quality of life improvement, intracranial response & extended survival with the HER2Climb regimen for patients with leptomeningeal disease from HER2+ bc. #ASCO24 @ASCO

Dr. Nadine Tung discusses TBCRC048 at #ASCO24 - olaparib is effective in patients with MBC with inherited PALB2 mutation or tumor acquired BRCA1 or BRCA2 mutation. Benefit in initial trial confirmed in a larger group of patients @TheTBCRC @OncoAlert

As seen today at #ASCO24 - TBCRC026, HER2-E and tumors with increased immune signaling more likely to respond to HER2-directed therapy in ER-/HER2+ breast cancer treated with neoadjuvant HP without chemo. @TheTBCRC @HennessyMaeve

RT @MKDeMeo: TBCRC048 is a collaborative IST led by #DFHCC and was open at 11 academic centers across the US via @TheTBCRC - thank you to t….

RT @awolff: #ASCO24 @TheTBCRC.

RT @MKDeMeo: Tomorrow #ASCO24 check out @NTungMD present #TBCRC048 olaparib expanded cohorts of gPALB2 and sBRCA MBC, one of the most rewar….

PI Dr. Tiffany Traina presenting the actively enrolling TBCRC058 trial #ASCO24 @RitaNandaMD . Find more info at:

In case you missed @GuiNaderMarta @elmayermd poster on TBCRC030! #ASCO24

ETHAN - groundbreaking new @TheTBCRC trial for male breast cancer led by PI Dr. Pablo Leone. #ASCO24. Learn more at

TBCRC058 aims to evaluate treatment in metastatic ER-negative / ER-low AR+ breast cancer. Learn more about the study at #ASCO24 @TheTBCRC

Baseline TILs assessed by visual examination or computational algorithms predict response to neoadjuvant chemotherapy in patients with TNBC. Come check out our poster at #ASCO24 today to learn more about TBCRC030! @TheTBCRC @elmayermd @GuiNaderMarta.